Shay Mitchell is Biore Skincare’s newest brand ambassador
BY Gina Acosta
NEW YORK — Bioré Skincare has chosen a popular ABC Family actress to be the new face of the brand for 2016 and star in advertising campaigns for the company’s new baking soda cleansers, which hit shelves earlier this year.
As the new face of Bioré Skincare, Shay Mitchell will help the brand introduce two new Baking Soda cleansers. Mitchell stars in ABC Family's "Pretty Little Liars," and is also a blogger and model. She is also the co-author of a novel about a trio of young Hollywood hopefuls, and the co-founder of a popular lifestyle website.
The new Bioré Baking Soda Pore Cleanser is a dual-action liquid cleanser that deep cleans and exfoliates. The Bioré Baking Soda Cleansing Scrub is a concentrated powder cleanser that foams up on contact with water.
Both products may be purchased in select food, drug, and mass merchant stores.
Lupin’s GAVIS pipeline brings generic insomnia treatment to market
BALTIMORE – Lupin Limited announced Tuesday that its U.S. subsidiary, Lupin Pharmaceuticals, has launched the first product from its GAVIS pipeline, Zolpidem Sublingual Tablets, 1.75 mg & 3.5 mg. The new entry is the generic equivalent of Purdue Pharma’s Intermezzo Sublingual Tablets, 1.75 mg & 3.5 mg.
Lupin received final approval from the United States Food & Drug Administration earlier, as well as final clearance from the FTC with 180 days of exclusivity.
Zolpidem Sublingual Tablets is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
Intermezzo had U.S. sales of $9.5 million, according to IMS for the moving annual total ended December 2015.
Pfizer walks away from Allergan deal following Treasury move on inversion
NEW YORK – Pfizer on Wednesday announced that the merger agreement between Pfizer and Allergan has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an “Adverse Tax Law Change” under the merger agreement.
That Treasury announcement referenced by Pfizer and Allergan makes it more difficult for companies to invert. “Treasury has taken action twice to make it harder for companies to invert. These actions took away some of the economic benefits of inverting and helped slow the pace of these transactions, but we know companies will continue to seek new and creative ways to relocate their tax residence to avoid paying taxes here at home,” stated Treasury Secretary Jacob Lew on Monday. “Today, we are announcing additional actions to further rein in inversions and reduce the ability of companies to avoid taxes through earnings stripping.”
“Pfizer approached this transaction from a position of strength and viewed the potential combination as an accelerator of existing strategies,” stated Ian Read, chairman and CEO Pfizer. “We remain focused on continuing to enhance the value of our innovative and established businesses. Our most recent product launches, including Prevnar 13 in Adults, Ibrance, Eliquis and Xeljanz, have been well-received in the market, and we believe our late stage pipeline has several attractive commercial opportunities with high potential across several therapeutic areas,” he said.
“We plan to make a decision about whether to pursue a potential separation of our innovative and established businesses by no later than the end of 2016, consistent with our original timeframe for the decision prior to the announcement of the potential Allergan transaction,” Read added. “As always, we remain committed to enhancing shareholder value.”
In connection with the termination of the merger agreement, Pfizer has agreed to pay Allergan $150 million for reimbursement of expenses associated with the transaction.
Loading Post Please Wait...